For example, young patients developing disseminated TB during primary infection owing to the impaired production of IFN-γ (such as those with IL12RB1 mutations) would benefit from targeted treatment with recombinant IFN-γ [67]. The gene discussed is IFNG; the disease is tuberculosis.